Next Phase Newsletter

The firm is a venture capital firm founded in 2012 and based in Missouri. The firm manages three healthcare and life sciences funds for a combined total of $60 million in assets under management. The firm’s first life science focused fund was launched in 2013 with $15 million of capital to invest. The firm looks to make equity investments of approximately $500k – $1 million into companies with additional capital reserved for follow on rounds. The firm looks to act as a bridge with its investments between the Seed and Series A round. The firm is also open to syndication with other investors for larger deals. The firm focuses its investments in the Midwest but is open to companies located throughout the US and makes approximately 6-8 investments per year.

The firm has recently launched a new healthcare fund in collaboration with another VC fund, resulting in the firm’s focus has shifted more Healthcare IT and Digital Health, with a specific focus on how healthcare delivery has changed during the COVID 19 pandemic. Examples of the subsectors of interest are: remote care, Healthcare IT for hospital efficiency, and response infrastructure systems. The firm is opportunistic in terms of indication.

The firm looks for management teams with domain experience, and is comfortable with working with incomplete or scientific founding teams. The firm prefers to take a board seat into companies following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a private investment firm based in New York. The firm is supported by a family who has invested in healthcare operating companies and real estate for over 30 years and seeks to invest in opportunities that align with their strategic interests. Investments in healthcare have included skilled nursing facilities, rehabilitation therapy, institutional pharmacy, hospice, mental health tech, healthcare tech, and home health. The firm looks to work with early stage companies where they can leverage their operating platform. As a private investor, the firm has a very flexible horizon and mandate – investment size can greatly vary on a deal-by-deal basis. The firm has about 20 companies in their its portfolio, and invests all across the USA.

The firm has a robust portfolio that ranges from healthcare to technology to consumer products. While the firm has a broad interest in healthcare, the firm is most interested in technologies that can leverage the firm’s operating platform and resources. The firm’s portfolio companies include workforce transformation, nurse staffing, medical billing, and Fintech that is focused on the healthcare sector, medical billing, and more. The firm also has a strong interest in technologies dedicated to mental & behavioral health. The firm is opportunistic in terms of stage of development. The firm does not consider therapeutics opportunities.

The firm seeks to partner with smart, thoughtful founders with a true commitment in their ideas. The firm is a hands-on investor and seeks to have an active role in their portfolio companies. As mentioned above, the firm is able to leverage its resources to support pilots and enable companies

to test new ideas. The firm can also support companies in enhancing their business models, implementing scale through partnerships, and share their own experiences in developing world-class brands.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is an investment management firm based in Tianjin, China. The firm manages multiple funds and is engaged in equity investment, asset management, merger and acquisition across several industries including healthcare. The firm’s healthcare portfolio includes multiple pharmaceutical companies. The size of investment varies depending on the deal, but the firm is investing from a 1 billion RMB fund for healthcare. The firm is currently seeking equity investment and licensing opportunities in China and the US. The firm is looking for companies with a China angle and has experience helping companies obtain CFDA approval.

Within healthcare, the firm is interested in medical devices, IVD, medical equipment, home-care products, and other healthcare-related technologies. The firm considers products that have at least completed prototype. The firm prefers products that have already obtained FDA clearance or approval, but it is happy to work with companies who are ~1 year away from FDA approval as well. In terms of indication areas, the firm is interested in diseases with large market potential in China, including oncology, reproductive health, cardiovascular diseases, and diabetes and metabolic disorders.

The firm seeks to work with experienced teams with strong sector knowledge. The firm is looking for products with a China angle and may request distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A VC fund based in the USA invests in many sectors, including cloud based enterprise SaaS, Property Tech, and life sciences & healthcare. Within the life sciences, the firm is interested in therapeutics, medical device, digital health and healthcare IT companies. The firm invests in Series A and later rounds, and can invest anywhere from $1-20M in the initial check, and may participate in follow-on rounds. The firm is generally focused on investing in companies based in North America, but will consider global companies if they have a large presence in the US and are focused on the US market.

The firm will invest in therapeutics, medical device, digital health and healthcare IT companies. Within therapeutics, the firm is seeking companies in IND or later stages. In addition, the firm is interested in platform technologies, and will also invest in AI or machine learning based drug discovery companies. The firm will not invest in single asset or single modality companies. For medical devices, the firm primarily invests in 510K pathway devices that are FDA approved. The firm will not invest in DTC devices, and is less likely to consider de novo or PMA devices as well. Furthermore, the firm is most interested in devices that have a continuing source of revenue, such as a software application component. For digital health and healthcare IT companies, The firm is primarily focused on companies with B2B services, and will not invest in digital therapeutics. The firm is interested in companies that have greater than of $3M in ARR.

The firm is willing to lead or co-invest, but will generally take a board seat if they lead the investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Canada is making seed and venture investments and usually seeks to be the first institutional capital in a company. Equity investments are the preferred capital structure; however convertible notes may be employed for seed investments. Initial investments may be as small as $1M (seed-stage companies) with up to $15M allocated over the life of the investment. The firm prefers to lead financing rounds of Canadian companies and co-lead investments based in the United States.

The firm is focused on investments in therapeutics, medtech and diagnostics. The firm is agnostic in terms of subsector and indication and invests in early pre-clinical up unto Phase III therapeutic assets with the caveat being that the capital needs of the company fall within the fund’s criteria for investment size. As for devices and diagnostics stage of development, the firm invests in products in development and in clinical settings given the aforementioned capital constraints for therapeutics. For medtech, the firm has a preference for 510(k) regulatory pathways but will also evaluate devices with a PMA pathway.

The firm has no strict criteria for management teams and will work with novice entrepreneurs, however those management teams with experience are favored. The firm looks to originate 2/3 of its investments in Canada and the rest in the United States, and typically seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm with offices in the USA invests in companies of all sectors that have some AI/ML component. Within healthcare, the firm invests in revenue-generating companies. The firm will not invest in any company that requires FDA approval. The firm invests primarily in the US, but reserves about 30% of their fund for investments in India. The firm invests in Series A and later companies, and will invest $0.5-2M per company.

The firm does not invest in therapeutics or medical devices, anything that requires FDA approval. The firm primarily invests in software-based companies, as long as the technology has an AI/ML component. This could include enterprise software, diagnostic image analysis or drug discovery platforms, as long as the therapeutics are then out-licensed, and not developed in house.

The firm can lead or co-invest, and will take a board or observer seat for larger check sizes. The firm is an active investor, and looks for management teams that are open to suggestion and are willing to benefit from the expertise of the firm and their network. The firm looks for companies that have at least $1M in ARR.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm with offices in Asia makes late venture and growth stage investments exclusively in the life sciences. The firm has raised 3 funds to date. The firm recently raised its third fund of USD 200 million in April 2014. The firm’s target investment size is USD 15-20 million per company and typically USD 5 million for cross-border investments. The firm primarily focuses on opportunities in China; however the firm is also interested in companies abroad that have a strong China angle or China strategy in near term (target market, R&D/manufacturing, sales, etc). The firm is actively seeking new investment opportunities.

The firm seeks to invest in late-stage assets that are on market or close to commercialization. The firm is interested in therapeutics/pharmaceuticals, medical devices, diagnostics, and healthcare services. For therapeutics, the firm will consider small molecules and biologics as well as biosimilars and reformulated drugs. At minimum, the product should be in Phase III of clinical trials. The firm may look at Phase II candidates that have a relatively less complicated clinical trial. For example, the firm will not consider biologics in Phase II. For indications, the firm focuses on products that address a large unmet medical need in China. This includes diabetes, cardiovascular, cerebrovascular, liver, and degenerative diseases. For medical devices, the firm is opportunistic in terms of subsectors. Similar to therapeutics, the firm focuses on indications relevant to China. The firm looks for devices that are very close to market or market approved.

The firm is only interested in companies that have a strong China angle or strategy. The firm typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.